Cochlear Limited Overview
Pro stress-test →Cochlear Limited provides implantable hearing solutions for children and adults worldwide, offering cochlear implant systems, sound processor upgrades, bone conduction systems, accessories, and other products. The company is the leading cochlear implant device manufacturer with around 60% global market share.
Strategic Profile
Pro stress-test →Cochlear was founded in 1981 and is headquartered in Sydney, Australia. Developed markets contribute 80% of group revenue where cochlear implants are the standard of care for children with severe to profound hearing loss, and the company actively targets the growing cohort of seniors in developed markets. In April 2022, Cochlear acquired Danish competitor Oticon Medical for A$170 million.
Competitive Landscape
Pro stress-test →Cochlear dominates the cochlear implant market with ~60% global share. Key competitors include MED-EL (Austria-based), Advanced Bionics (part of Sonova), and Oticon Medical (now acquired). The market is highly specialized with significant barriers to entry due to regulatory requirements, clinical evidence, and manufacturing complexity. Competition is intensifying in adjacent bone conduction and direct acoustic stimulation segments.
Industry Context
Cochlear Limited operates in Medical Devices - Implantable Hearing Solutions.
Key facts
Founded: 1981 · Headquarters: Sydney, Australia · Employees: 5,500 · Revenue: $1.5B · Market cap: $12.2B